Page 191 – The development of a new service for patients with hyperlipidaemia and ischaemic heart disease in Cwm Taf University Health Board

Dr David Cassidy

Full article featured online. 

References

1. NICE. Cardiovascular disease risk assessment and reduction including lipid modification. CG 181 2014. Available at: https://www.nice.org.uk/guidance/cg181
2. NICE. Alirocumab for treating hypercholesterolaemia and mixed dyslipidaemia. Technical appraisal guidance 393 2016. Available at: https://www.nice.org.uk/guidance/ta393
3. NICE. Evolocumab for treating hypercholesterolaemia and mixed dyslipidaemia. Technical appraisal guidance 394 2016. Available at: https://www.nice.org.uk/guidance/ta394